Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.

NCT01718379 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

132

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Lenalidomide
DRUG: Epoetin beta

Sponsor

Groupe Francophone des Myelodysplasies

Collaborators

[object Object]
[object Object]